CV Science

Florence Pinet PhD pharmacology

Course and current status

Position

1988            INSERM Researcher 2^nd class at INSERM U36 (P Corvol)

1992            INSERM Researcher 1st class at INSERM U36 (P Corvol)

1997            INSERM Research Director 2^nd class at INSERM U36 (P Corvol)

2000            INSERM Research Director 2^nd class at INSERM U744 (P Amouyel)

 Research laboratory : INSERM U744- IPL- 1 rue du professeur Calmette-59019 Lille cedex . Directeur : Pr P.AMOUYEL

_{Scientific activities}

1983            MASTER in Molecular and Cellular Pharmacology (Paris VI)

Role of glucocorticoides on angiotensinogen production by primary cultures of cultures hepatocytes (INSERM U36)

1987    PhD in Molecular and Cellular Pharmacology (Paris VI)

_{Establishment of human renin-producing from renal and extra-renal origin (INSERM U36)}

1984    Zurich University (Switzerland, Professor M. Celio)

Applications of immunohistochemistry techniques to culture of juxtaglomerular cells.

1989            Tsukuba University (Japan, Professor K. Murakami)

            Regulation of renin gene in chorionic cells using CAT reporter gene. 

1991    Zurich University (Switzerland, Professor A. Kurtz)

Intracellular calcium measurement in a single chorionic cell using fura-2.

1999                Visiting researcher at Harvard University (USA, MGH, Boston, Professor M. C.  Fishman) Morphological characterization of zebra fish presenting cardiac abnormalities.

Learned societies

_{1996- 2008  Board member of GRRC (Reflexion Group on Cardiovascular Research)}

2001-2010   Board member of SFHTA (French Society of Arterial Hypertension)

2004-2009   Board member of  cardiovascular scientific committee of « Fondation de France ».

2005-2009   Board member of European Council for Cardiovascular Research 

2008-2013      Board member of SFC (French Society of Cardiology)

 Prize

2003    Prize of cardiovascular research JP Binet (FRM)

2006            Labellisation of the research team by FRM

Scientific summary

After PhD studies in Paris (France) on regulation of human renin gene expression using different cell lines producing renin and transgenic mice, I developped transcriptional studies on endothelin system.

I moved in 2000 to Lille (France) and as leader of an Inserm team, I developed a translational research with the aim to find new biomarkers in cardiovascular diseases, mainly left ventricular remodeling post-myocardial infarction and abdominal aortic aneurysm, using differential proteomic analysis.

For that purpose, we were the first to establish the reference 2D maps of human macrophages and smooth muscle cells. We have developed proteomic techniques dedicated to human biological samples (plasma, serum, vascular cells): 2D-DIGE electrophoresis using saturating Cyanine-dyes, SELDI-TOF analysis. We have developed techniques allowing the analysis of “deep plasma” proteome and phosphorylation and O-N-acetyl-glucosaminylation. We have also the expertise of techniques allowing the verification and validation of the proteins selected from the proteomic analysis (western blot, immnuofluorescence and immunohistochemistry, ELISA).

We developed clinical studies recruiting patients precisely phenotyped for the cardiovascular diseases studied with biological samples collected for proteomic analysis. For abdominal aortic aneurysm and left ventricular remodeling post-infarction, we found several proteins modulated in diseased patients by differential proteomic analysis of vascular cells or plasma. More recently, using phosphoproteomic and an experimental model of myocardial infarction in animals, we found a decrease of phosphorylated troponin T in left ventricle of heart failure animals. We developed tools (specific antibodies) to detect the phosphorylated form of troponin T in plasma of the same animals. Then, we validated in patients with high left ventricular remodeling post-infarction, the decrease of phosphorylation of troponin T, suggesting that the level of phosphorylation of troponin T could be a new biomarker and help to predict this effect in high risk patients.

 Patent: WO 2010/133655 A1 (25 November 2010) Pinet F, Mulder P, Bauters C, Richard V.Post-translation modified cardiac troponin T as a biomarker of a risk for heart failure.